FGFR TYROSINE KINASE INHIBITORS AND ANTI-PDI AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 4, 2023
app pub date -
Feb 11, 2021
filing date -
Feb 12, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed herein are methods of treating urothelial carcinoma. In particular, the disclosed methods include combination therapies for the treatment of urothelial carcinoma comprising administering a fibroblast growth factor receptor (FGFR) inhibitor and an anti-PD1 antibody or antigen binding fragment thereof.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully